Clinical Research Directory
Browse clinical research sites, groups, and studies.
Thyroid Hormone Replacement After Coronary Artery Bypass Grafting for Patients With Subclinical Hypothyroidism
Sponsor: Seoul National University Bundang Hospital
Summary
The goal of this clinical trial is to find out whether levothyroxine reduces complications and improves the prognosis of patients with subclinical hypothyroidism (SCH) undergoing coronary artery bypass grafting (CABG). The main questions this study aims to answer are: • Does levothyroxine reduce major adverse cardiovascular events (MACE), including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and new arrhythmias, in SCH patients undergoing CABG? Researchers will compare patients who take levothyroxine with those who do not. Participants will: * Be randomly assigned to either receive levothyroxine or not * Start the medication one day before surgery if assigned to the treatment group. * Have regular follow-up visits to check thyroid function and cardiovascular events for up to five years after surgery.
Key Details
Gender
All
Age Range
19 Years - 90 Years
Study Type
INTERVENTIONAL
Enrollment
338
Start Date
2022-02-27
Completion Date
2037-02-26
Last Updated
2026-02-02
Healthy Volunteers
No
Conditions
Interventions
levothyroxine
Intervention description: Participants assigned to the LT4 group will begin receiving levothyroxine the day before CABG. The initial dose is 25 μg once daily, or 12.5 μg for participants weighing less than 60 kg. The dose will then be adjusted based on thyroid function test results to achieve target TSH levels of 0.4-2.0 μIU/mL.
Locations (1)
Department of Internal Medicine, Seoul National University Bundang Hospital
Seongnam-si, South Korea